Their inhibitors can induce cancer cell death, while also favoring an inflammatory response in AML cells avoiding immune surveillance [77].Checkpoint inhibition with PD-1/PD-L1 (e.g., nivolumab, pembrolizumab) or CTLA4 antibodies(e.g., ipilimumab) was evaluated in adult solid neoplasms, and AML is currently under investigation. This evidence concerns the gene CD274 and acute myeloid leukemia.